ICD-10 Coding for Chronic Myeloid Leukemia(C92.1, C92.10, C92.10B)
Explore comprehensive ICD-10 coding guidelines for chronic myeloid leukemia, including phase-specific codes and documentation requirements.
Complete code families applicable to Chronic Myeloid Leukemia
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C92.10 | Chronic myeloid leukemia, BCR/ABL-positive, in remission | Use when the patient is in remission with documented molecular response. |
|
| C92.11 | Chronic myeloid leukemia, BCR/ABL-positive, in relapse | Use when the patient shows evidence of relapse with rising BCR/ABL1 levels. |
|
| C92.12 | Chronic myeloid leukemia, BCR/ABL-positive, in accelerated phase | Use when the patient is in the accelerated phase with documented clinical features. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information
Essential facts and insights aboutChronic Myeloid Leukemia
Alternative codes to consider when ruling out similar conditions
Documentation & Coding Risks
Avoid these common issues when documenting Chronic Myeloid Leukemia.
Using unspecified CML code
Impact
Clinical: Leads to inappropriate treatment planning., Regulatory: Non-compliance with coding standards., Financial: Potential loss of reimbursement.
Mitigation
Always specify the phase of CML., Document molecular response.
Coding CML without specifying the phase
Impact
Reimbursement: Incorrect phase coding can lead to reimbursement issues., Compliance: Non-compliance with coding guidelines., Data Quality: Impacts the accuracy of clinical data.
Mitigation
Always document and code the specific phase of CML.
Phase documentation
Impact
Failure to document the phase of CML can lead to audit issues.
Mitigation
Implement phase-specific documentation templates.